HRMY operates in the biopharmaceutical sector focusing on rare neurological diseases. The company's financial ratios demonstrate strong compliance in debt (9.06%) and liquidity (25.87%) metrics across all standards, with non-permissible income at 0%. However, the interest income ratio, while currently low at 0.14%, has historical highs leading to flagged concerns. Overall, due to exclusion from major Shariah indices, the stock is classified as non-compliant, though suitable for review with purification. The compliance quality is moderate, reflecting solid recent performance but index and historical issues.